CNS volume 29 issue 5 Cover and Front matter.
- Published in:
- CNS Spectrums: The International Journal of Neuropsychiatric Medicine, 2024, v. 29, n. 5, p. f1, doi. 10.1017/S1092852924002438
- Publication type:
- Article
Works matching IS 10928529 AND DT 2024 AND VI 29 AND IP 5
Results: 122
1
2
Ketamine for the Treatment of Psychiatric Disorders: A Systematic Review and Meta-Analysis – CORRIGENDUM.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
3
A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain – CORRIGENDUM.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
4
Efficacy of esketamine for perinatal depression: a systematic review and meta-analysis – CORRIGENDUM.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
5
The Association Between Dextromethorphan/Bupropion with Alcohol and Substance Misuse: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS) – CORRIGENDUM.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
6
Visual release hallucinations presenting as psychosis – a scoping review.
- Published in:
- CNS Spectrums: The International Journal of Neuropsychiatric Medicine, 2024, v. 29, n. 5, p. 362, doi. 10.1017/S1092852924002281
- By:
- Publication type:
- Article
7
Effects of esketamine combined with dexmedetomidine on postoperative delirium and quality of recovery in elderly patients undergoing thoracoscopic radical lung cancer surgery: a randomized controlled trial.
- Published in:
- CNS Spectrums: The International Journal of Neuropsychiatric Medicine, 2024, v. 29, n. 5, p. 441, doi. 10.1017/S1092852924002177
- By:
- Publication type:
- Article
8
Association of multiple sclerosis with psychiatric disorders and homelessness among veterans in the United States Department of Veterans Affairs healthcare system.
- Published in:
- CNS Spectrums: The International Journal of Neuropsychiatric Medicine, 2024, v. 29, n. 5, p. 433, doi. 10.1017/S1092852924002165
- By:
- Publication type:
- Article
9
The historical opposition to psychedelic research and implications for credibility in psychiatry.
- Published in:
- CNS Spectrums: The International Journal of Neuropsychiatric Medicine, 2024, v. 29, n. 5, p. 300, doi. 10.1017/S1092852924002141
- By:
- Publication type:
- Article
10
Did Bipolar Disorder Enhance Jackson Pollock's Ability to Communicate Through Conscious and Unconscious Images (Polloglyphs)?
- Published in:
- 2024
- By:
- Publication type:
- Abstract
11
Effectiveness of Esketamine as a Treatment for Depression: A Real-World Survey of Disease Improvement.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
12
Cost Efficiency of Esketamine Nasal Spray Versus Quetiapine for Treatment Resistant Depression.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
13
Adverse Event Duration with Esketamine Versus Quetiapine XR in Adults With Treatment-Resistant Depression: A Subgroup Analysis of ESCAPE-TRD.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
14
Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (SAD).
- Published in:
- 2024
- By:
- Publication type:
- Abstract
15
Long-Acting Injectable Antipsychotic Treatment: Calculating Cost Offsets From Real-World Data.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
16
A Veteran with PTSD and Bipolar Disorder Type I with Psychotic Features.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
17
Feasibility of a Risperidone Implant for the Maintenance Treatment of Schizophrenia for up to 12 Months After a Single Administration.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
18
Impact of Progressive Muscle Relaxation on Psychological Symptoms on an Inpatient Psychiatric Unit.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
19
Mental-Health Related Disability Leave and Costs Among Patients with Treatment Resistant Depression Initiated on Esketamine and Conventional Therapies.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
20
Diagnostic Challenges of Late-Onset Mania versus Dementia with Behavioral Disturbances: A Case Report.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
21
Power-Up: Dissecting Neurobiological Mechanisms Underlying Internet Gaming Disorder.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
22
Resolution of COVID-19 Chemosensory Loss Upon COVID-19 Reinfection.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
23
TeleSCOPE 2.0: A Follow-Up Real-World Study of Telehealth for the Detection and Treatment of Drug-Induced Movement Disorders (DIMD).
- Published in:
- 2024
- By:
- Publication type:
- Abstract
24
Centanafadine Sustained Release in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: Secondary Outcomes From a Phase 2a Study.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
25
Characteristics and Outcomes of Hospitalized Psychiatric Inpatients Treated with Buprenorphine for Co-occurring OUD.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
26
A Review and Comparison of FDA-Approved Transcranial Magnetic Stimulation (TMS) Protocols for Depression.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
27
Proportion of Patients with Severe Postpartum Depression Achieving Response and Remission of Depressive and Anxiety Symptoms in the SKYLARK Study.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
28
Ctrl+ADHD: Navigating the Mechanisms Tethering Internet Gaming Disorder and ADHD.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
29
52-Week Open-Label Safety and Tolerability Trial of Centanafadine Sustained Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
- Published in:
- 2024
- By:
- Publication type:
- Abstract
30
Recognizing Practice Gaps Schizophrenia Diagnosis and Treatment: Results of a CME Accredited Survey.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
31
Kandinsky Clerambault Syndrome Manifesting as Tinnitus.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
32
Change in Depressive Symptoms Following Esketamine Initiation among Patients with Treatment-Resistant Depression in a Real-World Setting.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
33
A Thorough QT Study Using C-QTc to Evaluate the Effects of Centanafadine on Cardiac Repolarization.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
34
Efficacy and Safety of Lamotrigine in Pediatric Mood Disorders: Patients' Perspective.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
35
Introducing S.C.O.P.E. : Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement An Interactive Digital Platform to Educate on Schizophrenia Care.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
36
S.C.O.P.E. : Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement Platform The Interactive Long-Acting Injectable Antipsychotics Selector.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
37
Safety and Tolerability of KarXT (Xanomeline Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
38
Correlates of Psychiatric Polypharmacy Among Child and Adolescent Psychiatric Inpatients.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
39
Valbenazine Improves Tardive Dyskinesia with or Without Concomitant Antipsychotic Therapy: A Meta-Analysis of Three Long-Term Valbenazine Trials.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
40
Sustained Improvements in Chorea Associated with Huntington Disease with Once-Daily Valbenazine: Interim Results from a Long-Term Open-Label Study.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
41
Utilization of Psychiatric Pharmacogenomic Testing by Primary Care Physicians and Advanced Practice Providers: Confidence and Implementation Barriers.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
42
Clinical Characteristics of a Commercial Pharmacogenetic Testing Population.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
43
Determining Clinician Factors for Implementing LAIs and Defeating Barriers (DECIDE) Study: Describing Differences Between Clinicians Based on Their LAI Use and Archetype.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
44
Ketamine and Esketamine Use for Mood Disorders with Psychosis: A Systematic Review of Dissociative and Psychotic Symptoms.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
45
Familiarity with Psychiatric Pharmacogenomic Testing in Physicians and Advanced Practice Providers: Educational Opportunities.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
46
A Literature Review of Antipsychotic-Associated Obsessive-Compulsive Disorder/Obsessive Compulsive Symptoms in the Treatment of Schizophrenia.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
47
Assessment of Underdiagnosis of Tardive Dyskinesia by Geographic Region, Social Determinants, and Other Patient Characteristics.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
48
Pooled Analysis of EPS-Like Symptoms in the EMERGENT Program of KarXT in Schizophrenia.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
49
Curriculum Based CME Improves Healthcare Provider Knowledge and Competence in the Assessment and Management of Major Depressive Disorder.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
50
Repetitive Transcranial Magnetic Stimulation (rTMS) versus Transcranial Direct Current Stimulation (tDCS) for Depression: a review.
- Published in:
- 2024
- By:
- Publication type:
- Abstract